Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country entities : Amneal pharmaceuticals, inc. save search
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -1.08%
H: 1.09%
C: -0.55%
rtu first
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.33%
C: -2.64%
fda approval
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
Published: 2024-01-10 (Crawled : 14:30) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.7%
C: -3.16%
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
Published: 2023-10-12 (Crawled : 14:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 0.24%
H: 0.95%
C: -9.74%
Amneal to Report Third Quarter 2023 Results on November 7, 2023
Published: 2023-10-05 (Crawled : 12:30) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 0.71%
H: 0.95%
C: -7.8%
report results
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
Published: 2023-09-06 (Crawled : 22:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval injection
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 3.14%
H: 0.0%
C: -6.09%
fda approval
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
Published: 2023-07-03 (Crawled : 22:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -2.26%
H: 0.66%
C: 0.66%
xyrem fda authorized approval
Amneal Receives U.S. FDA Complete Response Letter for IPX203
Published: 2023-07-03 (Crawled : 22:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -2.26%
H: 0.66%
C: 0.66%
ipx203 fda response
Amneal to Participate at the 2023 Jefferies Healthcare Conference
Published: 2023-05-24 (Crawled : 13:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -0.44%
H: 2.68%
C: 1.79%
conference
Amneal Reports First Quarter 2023 Financial Results
Published: 2023-05-05 (Crawled : 11:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 2.17%
H: 4.79%
C: 2.13%
financial results
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -1.91%
H: 0.0%
C: -2.93%
year financial results
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -1.91%
H: 0.0%
C: -2.93%
fda drug application
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
Published: 2022-12-20 (Crawled : 17:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -0.46%
H: 0.47%
C: -2.33%
approval injection
Amneal to Report Third Quarter 2022 Results on November 4, 2022
Published: 2022-10-06 (Crawled : 19:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 0.9%
H: 1.78%
C: -1.33%
report results
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
Published: 2022-08-31 (Crawled : 21:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -0.85%
H: 3.43%
C: -6.87%
ipx203 treatment fda drug disease application parkinson’s submission
Amneal launches 4 new Generic products, including Vasopressin single-dose
Published: 2022-08-11 (Crawled : 23:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -1.91%
H: 0.0%
C: -5.19%
vasopressin
Amneal Appoints Deborah M. Autor to Board of Directors
Published: 2022-08-03 (Crawled : 13:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: 1.38%
H: 0.82%
C: -1.36%
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
Published: 2022-06-07 (Crawled : 13:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -3.07%
H: 2.72%
C: 2.72%
integration report esg
Amneal Reports First Quarter 2022 Financial Results
Published: 2022-05-04 (Crawled : 11:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -3.02%
H: 1.17%
C: -3.12%
results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.